Margins matter. The more Bio-Reference Laboratories (Nasdaq: BRLI) keeps of each buck it earns in revenue, the more money it has to invest in growth, fund new strategic plans, or (gasp!) distribute to shareholders. Healthy margins often separate pretenders from the best stocks in the market. That's why I check on my holdings' margins at least once a quarter. I'm looking for the absolute numbers, comparisons to sector peers and competitors, and any trend that may tell me how strong Bio-Reference Laboratories's competitive position could be.
Here's the current margin snapshot for Bio-Reference Laboratories and some of its sector and industry peers and direct competitors.
|
Company |
TTM Gross Margin |
TTM Operating Margin |
TTM Net Margin |
|---|---|---|---|
| Bio-Reference Laboratories |
49.3% |
10.6% |
5.8% |
| Genoptix (Nasdaq: GXDX) |
59.9% |
21.8% |
11.5% |
| Quest Diagnostics (NYSE: DGX) |
41.8% |
18.2% |
10.0% |
| Laboratory Corp. of America (NYSE: LH) |
41.9% |
20.3% |
11.7% |
Source: Capital IQ, a division of Standard & Poor's. TTM = trailing 12 months.
Unfortunately, that table doesn't tell us much about where Bio-Reference Laboratories has been, or where it's going. A company with rising gross and operating margins often fuels its growth by increasing demand for its products. If it sells more units while keeping costs in check, its profitability increases. Conversely, a company with gross margins that inch downward over time is often losing out to competition, and possibly engaging in a race to the bottom on prices. If it can't make up for this problem by cutting costs -- and most companies can't -- then both the business and its shares face a decidedly bleak outlook.
Of course, over the short term, the kind of economic shocks we recently experienced can drastically affect a company's profitability. That's why I like to look at five fiscal years' worth of margins, along with the results for the trailing 12 months (TTM), the last fiscal year, and last fiscal quarter (LFQ). You can't always reach a hard conclusion about your company's health, but you can better understand what to expect, and what to watch.
Here's the margin picture for Bio-Reference Laboratories over the past few years.
Source: Capital IQ, a division of Standard & Poor's. Dollar amounts in millions. FY= fiscal year. TTM = trailing 12 months.
(Because of seasonality in some businesses, the numbers for the last period on the right -- the TTM figures -- aren't always comparable to the FY results preceding them.)
Here's how the stats break down:
- Over the past five years, gross margin peaked at 52.2% and averaged 51.2%. Operating margin peaked at 10.6% and averaged 10.0%. Net margin peaked at 6.0% and averaged 5.7%.
- TTM gross margin is 49.3%, 190 basis points worse than the five-year average. TTM operating margin is 10.6%, 60 basis points better than the five-year average. TTM net margin is 5.8%, 10 basis points better than the five-year average.
With recent TTM operating margins exceeding historical averages, Bio-Reference Laboratories looks like it is doing fine.
If you take the time to read past the headlines and crack a filing now and then, you're probably ahead of 95% of the market's individual investors. To stay ahead, learn more about how I use analysis like this to help me uncover the best returns in the stock market. Got an opinion on the margins at Bio-Reference Laboratories? Let us know in the comments below.
- Add Bio-Reference Laboratories to My Watchlist.
- Add Genoptix to My Watchlist.
- Add Quest Diagnostics to My Watchlist.
- Add Laboratory Corp. of America to My Watchlist.
